Has the FDA Amendments Act of 2007 impaired drug development?
1B&D Consulting, Washington, DC, USA.
Abstract:
Perched at the midpoint of "v.4" of the Prescription Drug User Fee Act (PDUFA-4), better known as the US Food and Drug Administration Amendments Act (FDAAA), it seems presumptuous to draw critical conclusions based on an "interim analysis" of this work in progress. Because drug development is a complex process measured in decades, one must rely on "surrogate markers" to impute FDAAA outcomes. Even so, there are many indications that the FDAAA has doused the fires of innovation, in scope, spirit, and interim results.
Related Concept Videos
Drug Regulation
FDA Approved Drugs: Changes to Approved Drugs
Preclinical Development: Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Clinical Trials: Overview
Drug Control Governance: Regulatory Bodies and Their Impact


